PASG 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

PASG ▼ -18.08% at T+20d

NEUTRAL call ✗ call lost -18.08% · α vs SPY -22.28% · entry $6.25 → $5.12

Next anchor: T+60d in 5w

Last close $5.47 (close Jun 8) · -12.48% from $6.25 entry

Entry anchored
Apr 17, 11:36 AM ET
via Databento tick

T+1d

-1.12%

call -1.12% · α -0.47%

$6.18

settled 7w ago

T+5d

-8.64%

call -8.64% · α -9.55%

$5.71

settled 6w ago

T+20d

-18.08%

call -18.08% · α -22.28%

$5.12

settled 23d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Passage Bio disclosed updated interim data from its Phase 1/2 upliFT-D trial for PBFT02, showing reduced brain atrophy and stabilized plasma neurofilament levels in FTD-GRN patients. The FDA indicated a randomized controlled trial is required for registration, leading the company to evaluate strategic alternatives to maximize shareholder value.

Actionable Insight

Monitor for updates on the strategic review process and any potential partnerships or transactions. The FDA's requirement for a randomized controlled trial presents significant challenges that could impact the development path and valuation of PBFT02.

Key Facts

PBFT02-treated patients with CDR score 1 showed 64% reduction in whole brain atrophy and 54% reduction in frontotemporal cortex atrophy compared to natural history
Plasma NfL levels among PBFT02-treated patients showed average reduction of 1.0 pg/mL at 12 months
FDA indicated a randomized controlled registrational study design is required for PBFT02 in FTD-GRN indication
Company has initiated a review of strategic alternatives including merger, acquisition, or sale of assets
Cash runway expected through 1Q 2027

Financial Impact

No direct financial impact disclosed, but strategic review could lead to significant changes in company direction or valuation

cash runwaystrategic direction

Risk Factors

FDA's requirement for randomized controlled trial presents ethical, logistical, and financial challenges
Strategic review may not result in any transaction

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001104659-26-045219
Document: tm2612152d1_8k.htm	0001104659-26-045219
Document: tm2612152d1_ex99-1.htm	0001104659-26-045219
Document: 0001104659-26-045219-index-headers.html	0001104659-26-045219
Document: 0001104659-26-045219-index.html	0001104659-26-045219
Document: 0001104659-26-045219.txt	0001104659-26-045219

5 reports for PASG

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for PASG — sortable, filterable
	Type				Now
May 27, 2026 13d ago	8-K BEARISH ★ 6/10	$5.71 $6.00	▼ −5.08%	▼ −4.76%	$5.47 (+4.20%)
Apr 20, 2026 7w ago	8-K MIXED ★ 6/10	$6.25 $5.71	▼ −8.64%	▼ −9.55%	$5.47 (−12.48%)
Apr 20, 2026 7w ago	Press Release MIXED ★ 6/10	$6.25 $5.71	▼ −8.64%	▼ −9.55%	$5.47 (−12.48%)
Apr 7, 2026 9w ago	DEFA14A NEUTRAL ★ 2/10	$8.22 $10.86	▲ +32.20%	▲ +26.87%	$5.47 (−33.41%)
Mar 3, 2026 14w ago	Press Release NEUTRAL ★ 4/10	$8.00 $8.51	▲ +6.38%	▲ +6.85%	$5.47 (−31.63%)

US Market Status

Market Closed — Opens in 8h 33m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access